Medicare Enrolled
Dr. Amirali Popatia, M.D.
Optician · Richmond, TX
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Popatia from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Popatia?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Popatia
Dr. Amirali Popatia is an optician specialist in Richmond, TX, with 19 years of NPI registration. Based on federal Medicare data, Dr. Popatia performed 27,306 Medicare services across 873 unique beneficiaries.
Between the years covered by Open Payments, Dr. Popatia received a total of $18,397 from 71 pharmaceutical and/or device companies across 829 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in optician. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Popatia is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 3% volume in TX
$18,397 industry payments
Medicare Practice Summary
Medicare Utilization ↗27,306
Medicare services
Top 3% in TX for optician
873
Unique beneficiaries
$19
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~1,437 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Denosumab injection (Prolia/Xgeva) | 9,600 | $19 | $50 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
4,120 | $0 | $2 |
| Epoetin alfa injection (Retacrit) for anemia An injection of a biosimilar form of epoetin alfa used for non-end-stage renal disease purposes. The dose administered is 1000 units. |
3,960 | $6 | $40 |
| Normal saline infusion, 250 cc Administration of 250 cubic centimeters of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater fluid. |
1,064 | $1 | $15 |
| Injection, leucovorin calcium, per 50 mg | 1,025 | $3 | $10 |
| Injection, granisetron hydrochloride, 100 mcg | 930 | $0 | $5 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
785 | $22 | $75 |
| Fluorouracil injection, 500 mg Administration of a 500 mg dose of fluorouracil medication via injection. |
773 | $2 | $25 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
543 | $12 | $75 |
| Magnesium sulfate injection, per 500 mg An injection of magnesium sulfate administered in 500 mg increments. |
500 | $1 | $2 |
| 5% dextrose/normal saline (500 ml = 1 unit) | 462 | $1 | $15 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
458 | $97 | $325 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
396 | $1 | $2 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
353 | $10 | $50 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
348 | $91 | $175 |
| Injection, fosnetupitant 235 mg and palonosetron 0.25 mg | 318 | $340 | $1,200 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
311 | $49 | $200 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
298 | $21 | $150 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
268 | $133 | $200 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
209 | $11 | $50 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
209 | $66 | $125 |
| Intravenous push injection of new drug or substance A healthcare provider injects a new medication or substance directly into a vein using a push technique. |
152 | $42 | $125 |
| Intravenous drug injection A procedure involving the administration of a medication or substance directly into a vein. |
81 | $28 | $100 |
| Intravenous hydration infusion, 31-60 minutes Administration of fluids into a vein to maintain hydration. This procedure involves an infusion lasting between 31 and 60 minutes. |
55 | $25 | $100 |
| Office visit, established patient (10-19 min) An office visit for an existing patient lasting 10 to 19 minutes. The visit involves medical evaluation and management of the patient's condition. |
34 | $42 | $100 |
| New patient office visit, complex (60-74 min) | 32 | $168 | $350 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
22 | $48 | $120 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
9.9% high complexity
83.9% medium
6.2% routine
Industry Payment Transparency
Open Payments through 2024 ↗$18,397
Total received (2018-2024)
Avg $2,628/year across 7 years
Top 10% in TX for optician
71
Companies
829
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$15,732 (85.5%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$2,208 (12.0%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$457 (2.5%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$1,948
2023
$2,600
2022
$2,453
2021
$2,522
2020
$2,247
2019
$4,367
2018
$2,259
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Genentech USA, Inc.
$2,918
Amgen Inc.
$1,354
Merck Sharp & Dohme Corporation
$1,296
E.R. Squibb & Sons, L.L.C.
$1,216
AstraZeneca Pharmaceuticals LP
$1,031
Lilly USA, LLC
$869
Merck Sharp & Dohme LLC
$836
PFIZER INC.
$608
Daiichi Sankyo Inc.
$575
Eisai Inc.
$464
GENZYME CORPORATION
$377
GlaxoSmithKline, LLC.
$350
Ipsen Biopharmaceuticals, Inc
$342
EISAI INC.
$291
Spectrum Pharmaceuticals Inc.
$276
Seagen Inc.
$276
AVEO Pharmaceuticals, Inc.
$264
Astellas Pharma US Inc
$242
Coherus Biosciences Inc.
$227
Boehringer Ingelheim Pharmaceuticals, Inc.
$227
Regeneron Healthcare Solutions, Inc.
$216
TESARO, Inc.
$194
TerSera Therapeutics LLC
$194
Bayer HealthCare Pharmaceuticals Inc.
$193
Teva Pharmaceuticals USA, Inc.
$183
Gilead Sciences, Inc.
$176
Organon LLC
$168
Celgene Corporation
$167
PUMA BIOTECHNOLOGY, INC.
$157
JAZZ PHARMACEUTICALS INC.
$153
Seattle Genetics, Inc.
$145
Taiho Oncology, Inc.
$137
Mylan Institutional Inc.
$133
Aveo Pharmaceuticals, Inc.
$133
Puma Biotechnology, Inc.
$133
EMD Serono, Inc.
$119
Dendreon Pharmaceuticals LLC
$116
Exelixis Inc.
$107
Mirati Therapeutics, Inc.
$104
Novartis Pharmaceuticals Corporation
$102
Pharmacyclics LLC, An AbbVie Company
$96
Celltrion USA Inc.
$93
Myriad Genetic Laboratories, Inc.
$91
Foundation Medicine, Inc.
$86
TAIHO ONCOLOGY, INC.
$83
Amneal Pharmaceuticals LLC
$67
Sirtex Medical Inc
$64
Blueprint Medicines Corporation
$62
Bayer Healthcare Pharmaceuticals Inc.
$57
Deciphera Pharmaceuticals Inc.
$56
Heron Therapeutics, Inc.
$50
Jazz Pharmaceuticals Inc.
$48
Helsinn Therapeutics (U.S.), Inc.
$44
Clovis Oncology, Inc.
$43
Pharmacosmos Therapeutics Inc.
$40
Janssen Biotech, Inc.
$31
BeiGene USA, Inc.
$31
Myovant Sciences Inc.
$27
ARRAY BIOPHARMA INC
$27
Curium US LLC
$25
Adaptive Biotechnologies Corporation
$25
Progenics Pharmaceuticals, Inc.
$22
Immunocore Limited
$22
R-Pharm US LLC
$21
Stemline Therapeutics Inc.
$21
Telix Pharmaceuticals
$20
Janssen Pharmaceuticals, Inc
$19
SANOFI-AVENTIS U.S. LLC
$18
Incyte Corporation
$14
Kyowa Kirin, Inc.
$12
Kite Pharma, Inc.
$12
Top 3 companies account for 30.3% of total payments
Associated products mentioned in payments ›
ADCETRIS · AKYNZEO · ALIMTA · AVASTIN · Abraxane · Alecensa · Avastin · BAVENCIO · BENDEKA · BLENREP · BRAFTOVI · BRUKINSA · Bavencio · CALQUENCE · CINVANTI · COSELA · CYRAMZA · Cabometyx · Columvi · Detectnet · ELITEK · ENHERTU · ERBITUX · Enhertu · Erleada · FASLODEX · FOTIVDA · FOUNDATIONONE · FULPHILA · Fulphila · GAVRETO · GAZYVA · GILOTRIF · Halaven · Herceptin · IBRANCE · ILLUCCIX · IMFINZI · INFLECTRA · INLYTA · INQOVI · INREBIC · Imbruvica · Ixempra · JEVTANA · KANJINTI · KEYTRUDA · KIMMTRAK · KISQALI · KRAZATI · Kadcyla · Kyprolis · LIBTAYO · LONSURF · LUMAKRAS · LUTATHERA · LYNPARZA · Lenvima · Lonsurf · Lunsumio · MONJUVI · MVASI · MYCHOICE CDX · MYRISK · Monoferric · NERLYNX · NEXPLANON · Nerlynx · Neulasta · Nexavar · Nplate · ONTRUZANT · OPDIVO · OPDUALAG · ORGOVYX · Ogivri · Onivyde · Orserdu · PADCEV · POTELIGEO · PROVENGE · PYLARIFY · Padcev · Perjeta · PreciseTumor · Prolia · QINLOCK · RETEVMO · ROLVEDON · Revlimid · Rituxan · Rubraca · SIR-Spheres Microspheres · SOMATULINE DEPOT · SUSTOL · SUTENT · Stivarga · TABRECTA · TAGRISSO · TALZENNA · TECENTRIQ · TRUSELTIQ · TUKYSA · Tazverik · Tecentriq · Trodelvy · Truxima · Udenyca · VEGZELMA · VERZENIO · VYXEOS · Vectibix · Venclexta · WELIREG · XALKORI · XARELTO · XGEVA · Xermelo · ZEJULA · ZEPZELCA · Zoladex · Zynrelef · myRisk
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (86%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians. Total industry engagement is in the top 10% for optician in TX.
Equivalent to $67 per 100 Medicare services performed
Geographic Context
Opticians within 10 mi
319
Per 100K population
37.1
County median income
$113,409
Nearest hospital
OAKBEND MEDICAL CENTER
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Popatia is a mixed practice specialist, with above-average Medicare volume (top 3% in TX), with low-engagement industry engagement in the top 10% of TX peers, with 19 years of NPI registration.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Popatia experienced with denosumab injection (prolia/xgeva)?
Based on Medicare claims data, Dr. Popatia performed 9,600 denosumab injection (prolia/xgeva) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Popatia receive payments from pharmaceutical companies?
Yes. Dr. Popatia received a total of $18,397 from 71 companies across 829 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Popatia's costs compare to other opticians in Richmond?
Dr. Popatia's average Medicare payment per service is $19. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Popatia) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Opticians in Richmond
Browse opticians in Richmond ranked by procedure volume and transparency data.
Highest volume
Top Opticians in TX
Opticians ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Opticians in TX
Which TX opticians receive the most from drug and device companies.
By company
Genentech USA, Inc. Payments to Doctors
See all physicians who received payments from Genentech USA, Inc.
By company
Amgen Inc. Payments to Doctors
See all physicians who received payments from Amgen Inc.
By company
Merck Sharp & Dohme Corporation Payments to Doctors
See all physicians who received payments from Merck Sharp & Dohme Corporation.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology